Medication info
Subarood Tablets 20mg (Rosuvastatin Calcium (Unmicronized))

Subarood Tablets 20mg (Rosuvastatin Calcium (Unmicronized))

Prescription medicationOrally disintegrating TabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›20.8mg / 1 tablet
Manufacturer / importer
BC World Pharmaceutical Co., Ltd.
Appearance
White to light yellow round orodispersible tablet
Packaging
30 tablets/box [10 tablets/PTP × 3], 10 tablets/box [10 tablets/PTP × 1]
Approval status
Active

MFDS item code 202107782 · Approved 2021.12.02 · Insurance code 653103690

Summary

Main use
Improves dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is an orally disintegrating tablet. Place it on the tongue, allow it to dissolve, and take it without water. 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
BC World Pharmaceutical Co., Ltd.

Efficacy & effects

Improves dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial hypercholesterolemia of the heterozygous type
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used to treat hypercholesterolemia and various forms of dyslipidemia. It is particularly helpful in the treatment of patients with primary hypercholesterolemia and mixed hyperlipidemia who are not adequately controlled by diet and exercise. It is also used in conjunction with diet or other therapies in patients with homozygous familial hypercholesterolemia. This medication lowers total cholesterol and LDL cholesterol levels, helping to delay the progression of atherosclerosis and reducing the risk of stroke, myocardial infarction, and revascularization procedures in patients at high risk for cardiovascular disease. It is also used as an adjunct to diet in pediatric patients meeting certain criteria with familial hypercholesterolemia. Overall, this medication aids in improving blood lipid levels and reducing the risk of cardiovascular disease.

How to take

Adult dose

This medicine is an orally disintegrating tablet. Place it on the tongue, allow it to dissolve, and take it without water. 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, those who are allergic to any component of this medication or have severe liver dysfunction, as well as patients with muscle disorders, should not use it. Additionally, patients with very poor kidney function, women who are pregnant or nursing, and women of childbearing age who are not using adequate contraception should not take this medication. High-dose use is especially prohibited in patients at risk for muscle disorders. As this medication may affect liver function, caution should be exercised in patients who excessively consume alcohol or have a history of liver disease. It is advisable to repeat liver function tests before and during treatment. If symptoms such as myalgia or muscle weakness occur, the physician should be notified immediately, and discontinuation of the medication may be necessary. This medication should be used cautiously in patients at risk for muscle damage, and it is recommended to check muscle enzyme levels prior to treatment. In the event of acute illness or severe conditions, discontinuation of this medication may be necessary. This medication can interact with other drugs, so it is essential to inform the physician of any other medications being taken. In particular, co-administration with certain antivirals, immunosuppressants, and antifungal agents may increase the risk of muscle damage. Women who are pregnant or may become pregnant should not take this medication, and adequate contraception is essential. Nursing mothers should also avoid taking this medication. In the case of overdose, there is no specific antidote, and treatment should be symptomatic while monitoring liver function and muscle enzyme levels. This medication does not significantly affect the ability to drive or operate machinery, but caution should be exercised as dizziness may occur.

Side effects

  • Allergic reactions including angioedema
  • diabetes
  • headache
  • dizziness
  • constipation
  • nausea
  • abdominal pain
  • pancreatitis
  • itching
  • rash
Show 48 more
  • urticaria
  • myalgia
  • myopathy
  • rhabdomyolysis
  • weakness
  • polyneuropathy
  • amnesia
  • peripheral neuropathy
  • myasthenia gravis
  • cough
  • dyspnea
  • diarrhea
  • ophthalmoplegia
  • thrombocytopenia
  • jaundice
  • hepatitis
  • increased transaminases
  • Stevens-Johnson syndrome
  • drug eruption resembling psoriasis
  • lupus-like syndrome
  • muscle rupture
  • arthralgia
  • immune-mediated necrotizing myopathy
  • hematuria
  • edema
  • depression
  • sleep disorders
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • fatal and non-fatal hepatic failure
  • cognitive impairment
  • increased ALT
  • chest pain
  • muscle cramps
  • gout
  • erectile dysfunction
  • increased AST
  • joint pain
  • fatigue
  • numbness
  • paresthesia
  • discomfort in the chest
  • loss of appetite
  • abdominal distension
  • abnormal liver function tests
  • syncope
  • generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is advisable to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature to ensure the medication's efficacy and safety over time.

Appearance and packaging

Appearance

White to light yellow round orodispersible tablet

Package unit

30 tablets/box [10 tablets/PTP × 3], 10 tablets/box [10 tablets/PTP × 1]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.